Biotechnology News and Research

RSS

Pennsylvania Bio issues new report on Pennsylvania's bioscience companies' efforts for cancer research

Pennsylvania Bio today issued a new report on cancer that details the research happening through Pennsylvania companies to develop new products to diagnose and treat cancer.

12 Sep 2010

Johns Hopkins added as second clinical trial site in Tengion Neo-Urinary Conduit Phase I clinical trial

Tengion, Inc., a leader in regenerative medicine, announced today it has added The Johns Hopkins Hospital in Baltimore, Maryland as a second clinical trial site for its Phase I clinical trial of the Company's lead product candidate, the Tengion Neo-Urinary Conduit™, in bladder cancer patients requiring bladder removal.

10 Sep 2010

Resverlogix announces key changes to Phase 2 ASSURE trial

Resverlogix Corp. announces that the Company's Phase 2 clinical trial, called ASSURE (ApoA-1 Synthesis Stimulation in Acute Coronary Syndrome patients), has made important modifications to the design of the trial which have the potential to demonstrate a more powerful endpoint for the planning of future clinical trials for RVX-208.

10 Sep 2010

Good Start Genetics to develop pre-pregnancy genetic test with completed $18M Series A financing

Good Start Genetics, Inc., today announced the completion of an $18 million Series A financing. The proceeds of this financing will be used to complete the development and launch of the Company's pre-pregnancy genetic test, which utilizes advanced DNA sequencing technology to screen for a panel of genetic disorders including those recommended by the American Congress of Obstetricians and Gynecologists (ACOG) and the American College of Medical Genetics (ACMG).

10 Sep 2010

Ortho Biotech unblinded abiraterone acetate Phase 3 study for prostate cancer patients

Ortho Biotech Oncology Research & Development, a unit of Cougar Biotechnology, Inc., today announced that it has unblinded the Phase 3 study of abiraterone acetate plus prednisone for the treatment of patients with metastatic advanced prostate cancer (also referred to as castration-resistant prostate cancer) whose disease has progressed following treatment with one or two chemotherapy regimens at least one of which contained docetaxel.

10 Sep 2010

395 new vaccines being developed for infectious diseases: PhRMA

Critical challenges remain in the centuries-old battles against infectious diseases, particularly as bacteria and viruses mutate and as the threat of bioterrorism grows. Responding to this need, America's biopharmaceutical research companies this year have 395 new medicines and vaccines in the pipeline to fight infectious diseases. All 395 are in later stages of development, meaning in clinical trials or under Food and Drug Administration (FDA) review.

10 Sep 2010

USIBC to embark Life Sciences Executive Mission for India

The U.S.India Business Council will embark on a Life Sciences Executive Mission to coincide with the Biotechnology Industry Organization's First Annual International Partnering Conference in Hyderabad, India from September 21-22. The mission will be led by Amgen's Dr. Romi Singh, Executive Director of Global Regulatory Affairs and Safety.

10 Sep 2010

Using opioids at end-of-life care proves effective to control pain

Patients who choose to spend their last days at home with specialized care and monitoring can safely be given opioids to control pain and other symptoms without reducing survival time, according to a study published in Journal of Palliative Medicine (JPM), a peer-reviewed journal from Mary Ann Liebert, Inc.

10 Sep 2010

Numerate awarded new contract by Defense Threat Reduction Agency

Numerate, Inc. announced today that it has been awarded a new three-year contract by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense, to adapt its pioneering small-molecule drug design platform to the rapid design and optimization of drugs against biowarfare agents.

10 Sep 2010

Koronis Pharmaceuticals to present KP-1461 clinical trial data at ICAAC Conference

Koronis Pharmaceuticals, Inc., a biotechnology company focused on the development of antiviral therapeutics, today announced that clinical trial data demonstrating that the Company's lead HIV drug, KP-1461, resulted in increased HIV mutations consistent with the Viral Decay Acceleration mechanism will be featured in a late-breaker oral presentation by James Mullins, Ph.D., Professor of Microbiology and Medicine at the University of Washington, at the upcoming 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Boston, MA.

10 Sep 2010

Children with severe, therapy-resistant asthma more likely to have poorer lung function: SARP

A subset of children with asthma suffers from severe, treatment-resistant disease associated with more illness and greater allergic hypersensitivity, according to the results of the National Heart, Blood, and Lung Institute's Severe Asthma Research Program, presented in a recently published article in Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal published by Mary Ann Liebert, Inc..

10 Sep 2010

Shire announces expansion of Human Genetic Therapies pipeline

Shire plc, the global specialty biopharmaceutical company, today announced the expansion of its Human Genetic Therapies pipeline through the exclusive license, in markets outside of North America, for the activin receptor type IIB class of molecules being developed by Acceleron Pharma Inc., a private biotechnology company based in Cambridge, Massachusetts.

10 Sep 2010

Special journal issue highlights obsessive compulsive disorder and Tourette's disorder therapies

Pediatric onset obsessive compulsive disorder (OCD) and Tourette's disorder (TD) share similarities in their underlying genetic and environmental factors, psychiatric features, and treatment methods. Advances in understanding the neurobiological basis of these disorders and discovering new and more effective therapies are highlighted in a special issue on OCD and TD in Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal published by Mary Ann Liebert, Inc.

10 Sep 2010

ASNM to hold annual conference on nanomedicine

There is enormous excitement and expectation surrounding the multidisciplinary field of nanomedicine the science and technology of diagnosing, treating and preventing disease using nanotechnology. The American Society for Nanomedicine (ASNM) is holding its second annual conference on October 14-16, 2010 in the Washington, D.C. area, where some of the biggest stakeholders in this emerging technology operate and practice.

10 Sep 2010

FerroKin BioSciences initiates international Phase 2 study of FBS0701

FerroKin BioSciences today announced the initiation of an international Phase 2 study of FBS0701, a novel once-daily iron chelator in development for the treatment of transfusional iron overload. The Phase 2 study will assess the safety, tolerability, and pharmacodynamics of FBS0701.

10 Sep 2010

USPTO issues patent for Advaxis’ live Listeria HER2/neu immunotherapy

The U.S. Patent and Trademark Office has issued to Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, patent number 7,784,729 titled "Methods and Compositions for Immunotherapy of Cancer," based upon patent application 10/949,667.

10 Sep 2010

Noscira receives FDA approval for Tideglusib drug to treat PSP

Noscira, a Grupo Zeltia subsidiary specialized in research and development of drugs to treat neurodegenerative diseases, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to its neuroprotector drug Tideglusib (ZentylorTM) to treat Progressive Supranuclear Palsy (PSP), a fast-advancing fatal degenerative brain disorder.

10 Sep 2010

NovaSterilis issued US patent

NovaSterilis Inc. has been issued US Patent # 7,771,652 B2 for “Combined Use of an Alkaline Earth Metal Compound and a Sterilizing Agent to Maintain Osteoinduction Properties of a Demineralized Bone Matrix”

9 Sep 2010

Patheon third-quarter total revenues decrease 0.7% to $163.3 million

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today its results for the third quarter and nine months ended July 31, 2010. Total revenues for the third quarter were $163.3 million or 0.7% lower than the same period last year. Excluding currency fluctuations, current year third quarter revenues would have increased by approximately 3.9% versus the same period last year.

9 Sep 2010

Scientists develop new strategy for quicker detection of biomarkers that indicate disease

Scientists at the UK's National Physical Laboratory have developed a new strategy for quicker and more precise detection of biomarkers - proteins which indicate disease. The work could pave the way for new tools to detect early stages of Alzheimer's and cancer at the molecular level.

9 Sep 2010

Biotechnology News and Research

Pennsylvania Bio issues new report on Pennsylvania's bioscience companies' efforts for cancer research

Johns Hopkins added as second clinical trial site in Tengion Neo-Urinary Conduit Phase I clinical trial

Resverlogix announces key changes to Phase 2 ASSURE trial

Good Start Genetics to develop pre-pregnancy genetic test with completed $18M Series A financing

Ortho Biotech unblinded abiraterone acetate Phase 3 study for prostate cancer patients

395 new vaccines being developed for infectious diseases: PhRMA

USIBC to embark Life Sciences Executive Mission for India

Using opioids at end-of-life care proves effective to control pain

Numerate awarded new contract by Defense Threat Reduction Agency

Koronis Pharmaceuticals to present KP-1461 clinical trial data at ICAAC Conference

Children with severe, therapy-resistant asthma more likely to have poorer lung function: SARP

Shire announces expansion of Human Genetic Therapies pipeline

Special journal issue highlights obsessive compulsive disorder and Tourette's disorder therapies

ASNM to hold annual conference on nanomedicine

FerroKin BioSciences initiates international Phase 2 study of FBS0701

USPTO issues patent for Advaxis’ live Listeria HER2/neu immunotherapy

Noscira receives FDA approval for Tideglusib drug to treat PSP

NovaSterilis issued US patent

Patheon third-quarter total revenues decrease 0.7% to $163.3 million

Scientists develop new strategy for quicker detection of biomarkers that indicate disease

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News